Statin Neuroprotection and Carotid Endarterectomy: Safety Feasibility and Outcomes

  • STATUS
    Recruiting
  • End date
    Apr 21, 2022
  • participants needed
    1000
  • sponsor
    Columbia University
Updated on 21 January 2021
atorvastatin
stroke
neurological symptoms
ischemia
statin
cerebral infarction
transient ischemic attack
endarterectomy
arterial stenosis

Summary

The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as outcome measure. Study will recruit patients based on their preexisting statin regimen.

The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against eCD.

Description

Carotid endarterectomy (CEA) is a common surgery performed to reduce the risk of stroke in patients with carotid artery narrowing. Statins, a class of drugs usually used to lower blood cholesterol, may protect the brain after surgery. Specific statins have been shown to protect the brain after surgery when compared to others. eCD affects about 25% of patients undergoing CEA and about 15% of undergoing asymptomatic CEA. It is associated with marked elevations in tissue markers of cerebral injury and is associated with earlier post-CEA mortality. This clinically significant, but subtle, cerebral injury is 10 times more common than stroke and its mechanism appears to be similarly related to regional hypoperfusion and ischemia. It is imperative to determine in a prospective randomized trial whether alteration/increase of preoperative statin regimens leads to improved neurologic outcome and an even lower incidence of stroke and possibly greater survival.

In order to optimally design and conduct such a trial it is critical to: 1) explore the safety and feasibility of altering statin regimen acutely (approximately 2 weeks) before CEA, and 2) clearly establish the neuroprotective outcome of an acute alteration in statin regimen. This would promote a better understanding of statin neuroprotection in humans and determine the statin treatment that affords the most neuroprotection in patients undergoing one of the most commonly performed procedures in the US.

Details
Condition Cerebrovascular accident, Carotid Artery Stenosis, Arterial Occlusive Disease, CAROTID ARTERY DISEASE, Occlusions, Stroke, cerebrovascular accidents, strokes, cerebral
Treatment Atorvastatin, Placebo, Statin
Clinical Study IdentifierNCT02850081
SponsorColumbia University
Last Modified on21 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years of age
Patient is currently on atorvastatin or simvastatin or rosuvastatin or statin nave (no statins in the last 30 days)
The patient has unilateral or bilateral carotid artery stenosis that is considered severe (carotid artery diameter reduction 70%) as defined by
Peak systolic velocity of at least 230 cm/s plus at least one of these
End diastolic velocity 100 cm/s OR
CTA showing 70% stenosis OR
MRA showing 70% stenosis
This stenosis has not caused any stroke, transient cerebral ischemia, or other relevant neurological symptoms in the past
The patient's attending doctor(s) (PMD, cardiologist, vascular/neurosurgeon) AND the patient have decided to proceed with a CEA to treat the patient's severe carotid stenosis
The patient has no known circumstance or condition likely to preclude 1 year follow-up or adherence to the study protocol
The patient is independent in their Activities of Daily Living at baseline
Patient has the ability to provide informed consent

Exclusion Criteria

Patient has underlying disease other than atherosclerosis (i.e. autoimmune disease, known active malignancy)
Patient has documented dementia or screens out based on abnormal Baseline MoCA (25) and AD8 (2)
Patient's life expectancy is < 12 months
Patient has advanced renal failure (serum creatinine > 2.5 mg/dL)
Patient has evidence of severe congestive heart failure or has history of end-stage cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina)
Patient has history of intolerance or allergic reaction to any statins (myotoxicity, hepatic dysfunction, rash, etc.)
Patient has received an investigational drug within 30 days
Patient is pregnant or lactating
Patient is currently taking any of the following which have been shown to interact with atorvastatin and/or simvastatin and/or rosuvastatin (as per current drug package inserts)
Cyclosporine
HIV Protease Inhibitors/Antivirals (e.g. rotanavir or plus rotanavir, tipranavir, lopinavir, boceprevir, saquinovir, darunavir, fosamprenavir, nelfinavir, efavirenz/tenofobir, atazanavir, simeprevir)
Hep C Protease Inhibitor/Antivirals (e.g. telapravir)
Antibiotics (i.e. cobicistat-containing products like Tybost, rifampin/rifampicin, clarithromycin, telithromycin, erythromycin)
Anti-fungals (i.e. itraconazole, ketoconazole, posaconazole, voriconazole, fluconazole); Gemfibrozil; Other Fenofibrates (e.g. Tricor, fibric acid)
Niacin > 1g/day or statins in combination with niacin (e.g. Vytorin, Simcor)
Colchicine
Danazol
Calcium Channel Blockers: Diltiazem, Varapamil
Dronedarone
Amiodarone
Digoxin
Ranolazine
Nefazodone
Warfarin/Coumadin
Lomitapide
Grapefruit juice > 1.2 liters/day (40.5 ounces/day)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note